KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2022 / Cilt: 6 - Sayı: 2

Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Osman KÖSTEK
Evrim ABAMOR
Sermin ÇOBAN KÖKTEN
Hatice ODABAŞ
Mahmut Emre YILDIRIM
Aysun KÜÇÜKÖZ UZUN
Murat AYHAN
Nedim TURAN
Deniz TATAROĞLU ÖZYÜKSELER
Sayfa
165–175
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

PostSUVmax and PostSULpeak values ≤1.15 and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 61.8% and 61.8%, and 73.3% and 77.0%, respectively, for the breast (p81% values and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 80.0% and 81.8%, and 80.0% and 60.7%, respectively, for the breast (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: To investigate the importance of FDG PET/CT in predicting pathologic complete response (pCR) in primary breast lesions and axillary lymph nodes of patients with local, advanced breast cancer who were given neoadjuvant chemotherapy (NAC).
📊
Temel Bulgular & Veri:Results: Our study included 121 patients in total and 34 patients (28.1%) had a complete response in the breast, and 53 patients (43.8%) had a complete response in axillary lymph nodes.
💡
Sonuç & Katkı:PostSUVmax and PostSULpeak values ≤1.15 and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 61.8% and 61.8%, and 73.3% and 77.0%, respectively, for the breast (p81% values and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 80.0% and 81.8%, and 80.0% and 60.7%, respectively, for the breast (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: To investigate the importance of FDG PET/CT in predicting pathologic complete response (pCR) in primary breast lesions and axillary lymph nodes of patients with local, advanced breast cancer who were given neoadjuvant chemotherapy (NAC). Methods: One hundred twenty-one patients who had FDG PET/CT and underwent surgery due to local, advanced breast cancer before and after NAC were involved in the study. SUVmax and SULpeak values before and after NAC were evaluated using FDG PET/CT and post-surgical responses were re-evaluated. Results: Our study included 121 patients in total and 34 patients (28.1%) had a complete response in the breast, and 53 patients (43.8%) had a complete response in axillary lymph nodes. PostSUVmax and PostSULpeak values ≤1.15 and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 61.8% and 61.8%, and 73.3% and 77.0%, respectively, for the breast (p81% values and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 80.0% and 81.8%, and 80.0% and 60.7%, respectively, for the breast (p

🔖

Bu Makaleye Atıf Yap

KÖSTEK, O., ABAMOR, E., KÖKTEN, S. Ç., ODABAŞ, H., YILDIRIM, M. E., UZUN, A. K., AYHAN, M., TURAN, N., ÖZYÜKSELER, D. T. (2022). Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 2, 165–175. https://ajindex.com/articles/508545

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin North Am 2007;87:379–98, ix
  2. Lee SC, Grant E, Sheth P, Garcia AA, Desai B, Ji L, et al. Accuracy of contrast-enhanced ultrasound compared with magnetic resonance imaging in assessing the tumor response after neoadjuvant chemotherapy for breast cancer. J Ultrasound Med 2017;36:901–11
  3. Man VC, Cheung PS. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer. Hong Kong Med J 2017;23:251–7
  4. Wahl RL. Positron Emission Tomography (PET): an update on applications in breast cancer. Breast Dis 1998;10:165–75
  5. Kim SJ, Kim SK, Lee ES, Ro J, Kang Sh. Predictive value of [18F] FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2004;15:1352–7
  6. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785–808
  7. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254–62
  8. Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014;260:608–14;discussion 614–6
  9. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36:1551–7
  10. Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 2001;45:257–68
  11. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861–6
  12. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700–8
  13. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, et al